Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Sanofi · найдено 123

Sanofi
Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
123 исследования
Завершено Фаза III Россия
riferminogene pecaplasmid; Placebo (for riferminogene pecaplasmid) · Sanofi

A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions

525 участников во всех странах ClinicalTrials.gov EFC6145
Завершено Фаза II–III Россия
AVE7688; Losartan-potassium · Sanofi

Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension

1 940 участников во всех странах ClinicalTrials.gov DFI6032
Прекращено Фаза III Россия
Rimonabant; Glimepiride; Metformin · Sanofi

A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin

508 участников во всех странах ClinicalTrials.gov EFC10007
Завершено Фаза III Россия
Insuline Glulisine · Sanofi

Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy

Москва 1 центр 142 участника во всех странах ClinicalTrials.gov HMR1964A_3505
Завершено Фаза III Россия
Alfuzosin; Placebo · Sanofi

12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension

Москва 1 центр 172 участника во всех странах ClinicalTrials.gov EFC5722
Завершено Фаза IV Россия
Insulin Glargine; Glimepiride; Insulin Glulisine; Metformin · Sanofi

Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.

Москва 1 центр 106 участников во всех странах ClinicalTrials.gov HMR1964A_4002
Завершено Фаза III Россия
Clopidogrel (SR25990); placebo · Sanofi

International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt

906 участников во всех странах ClinicalTrials.gov EFC5314
Завершено Фаза II–III Россия
docetaxel (XRP6976); cisplatin; 5-fluorouracil (5-FU) · Sanofi

A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Москва 1 центр 568 участников во всех странах ClinicalTrials.gov EFC6051
Прекращено Фаза III Россия
25 mg/day AVE5530; 50 mg/day AVE5530; placebo · Sanofi

A Multicenter, Double-blind, Randomized, 12-month, Placebo-controlled Study to Evaluate the Lipid-lowering Effect, Safety and Tolerability of AVE5530 25 mg/Day and 50mg/Day When Added to Ongoing Stable Statin Therapy (HMG-CoA Reductase Inhibitors) in Patients With Primary Hypercholesterolemia

1 015 участников во всех странах ClinicalTrials.gov EFC6910
Завершено Фаза III Россия
Satavaptan; placebo · Sanofi

Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver

463 участника во всех странах ClinicalTrials.gov EFC4492
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo; Metformin · Sanofi

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin

680 участников во всех странах ClinicalTrials.gov EFC6014
Прекращено Фаза III Россия
Idrabiotaparinux sodium; Warfarin; Placebo (for idrabiotaparinux); Placebo (for warfarin); Avidin; Placebo (for avidin) · Sanofi

A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

3 773 участника во всех странах ClinicalTrials.gov EFC10295
Завершено Фаза III Россия
Clopidogrel (SR25990); Placebo · Sanofi

A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy

Москва 1 центр 3 491 участник во всех странах ClinicalTrials.gov EFC5133
Завершено Фаза III Россия
SR58611A · Sanofi

An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder

366 участников во всех странах ClinicalTrials.gov EFC5893
Завершено Россия
Insulin glargine (U300) · Sanofi

A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo® Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus

4 589 участников во всех странах ClinicalTrials.gov OBS14708
Прекращено Фаза III Россия
Satavaptan; placebo · Sanofi

Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.

241 участник во всех странах ClinicalTrials.gov EFC6682
Завершено Фаза III Россия
Teriflunomide; Placebo (for teriflunomide) · Sanofi

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses

Москва 1 центр 1 088 участников во всех странах ClinicalTrials.gov EFC6049
Завершено Фаза II Россия
AVE5530; placebo; ezetimibe · Sanofi

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Ezetimibe-Calibrated, Multicenter Study Evaluating the Safety and Efficacy of Four Doses and Two Dose-Regimens of AVE5530 Over 4 Weeks in Patients With Mild to Moderate Primary Hypercholesterolemia

206 участников во всех странах ClinicalTrials.gov DRI6589
Прекращено Фаза III Россия
Volinanserin; Placebo · Sanofi

Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study

1 847 участников во всех странах ClinicalTrials.gov LTE6673

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.